Skip to Content

Join the 'Actemra' group to help and get support from people like you.

Actemra News

FDA Approves Genentech’s Actemra (tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome

Posted 31 Aug 2017 by Drugs.com

South San Francisco, CA – August 30, 2017 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Actemra® (tocilizumab) intravenous injection for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in patients two years of age and ...

Tocilizumab Beats Steroids for Controlling Blood Vessel Inflammation in Study

Posted 26 Jul 2017 by Drugs.com

WEDNESDAY, July 26, 2017 – The drug tocilizumab performs better than steroids in treating the most common form of blood vessel inflammation known as giant cell arteritis, a new study has shown. The phase 3 clinical trial of 251 patients confirmed that tocilizumab (Actemra) reduced symptoms and also the need for high-dose steroid treatment for the condition. Phase 3 clinical trials represent the ...

FDA Approves Actemra (tocilizumab) Subcutaneous Injection for Giant Cell Arteritis

Posted 23 May 2017 by Drugs.com

May 22, 2017 – The U.S. Food and Drug Administration today expanded the approved use of subcutaneous Actemra (tocilizumab) to treat adults with giant cell arteritis. This new indication provides the first FDA-approved therapy, specific to this type of vasculitis. “We expedited the development and review of this application because this drug fulfills a critical need for patients with this serious ...

Actemra Approved for Certain Blood Vessel Inflammation

Posted 22 May 2017 by Drugs.com

MONDAY, May 22, 2017 – The injected drug Actemra (tocilizumab) has been approved by the U.S. Food and Drug Administration to treat adults with giant cell arteritis, an inflammation of the blood vessels (vasculitis). In a media release Monday, the FDA said this form of vasculitis mostly involves blood vessels of the head. Traditional therapy includes large doses of anti-inflammatory drugs called ...

New Treatments Helping Kids With Juvenile Arthritis

Posted 20 Jul 2016 by Drugs.com

WEDNESDAY, July 20, 2016 – New treatments for juvenile arthritis offer hope to children with the chronic autoimmune condition, doctors say. Scientists are still working to understand what causes juvenile arthritis and how to stop its progression. But, kids coping with its effects have reason to be optimistic, according to Dr. Nikolay Nikolov, a rheumatologist and clinical team leader at the U.S. ...

Genentech Gains FDA Approval for New Subcutaneous Formulation of Actemra for use in Adult Patients Living with Moderately to Severely Active Rheumatoid Arthritis

Posted 22 Oct 2013 by Drugs.com

Genentech Gains FDA Approval for New Subcutaneous Formulation of Actemra® for use in Adult Patients Living with Moderately to Severely Active Rheumatoid Arthritis     This is the sixth FDA approval for Actemra in four years, following previous approvals for the treatment of adults with moderately to severely active rheumatoid arthritis and children two years of age and older wit ...

FDA Approves Actemra for Children with Polyarticular Juvenile Idiopathic Arthritis

Posted 30 Apr 2013 by Drugs.com

BASEL, April 30, 2013 – Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Actemra (tocilizumab) for the treatment of polyarticular juvenile idiopathic arthritis (PJIA). The medicine can be used in children two years of age and older with active disease. Actemra can be given alone or in combination with methotrexate (MTX) in people with PJIA. PJIA is a form of ...

Drugs Hold Promise for Severe Juvenile Arthritis Patients

Posted 19 Dec 2012 by Drugs.com

WEDNESDAY, Dec. 19 – Children who suffer from a rare and painful form of arthritis that's accompanied by fever and rashes may soon have more treatment options. Two studies published in the Dec. 20 issue of the New England Journal of Medicine suggest that two drugs – canakinumab and tocilizumab – reduce symptoms, including severe joint pain experienced by children with systemic juvenile ...

Newer Rheumatoid Arthritis Drugs Don't Raise Cancer Risk: Study

Posted 6 Sep 2012 by Drugs.com

THURSDAY, Sept. 6 – A new review finds that rheumatoid arthritis medications known as biologics don't raise the risk of cancer, contrary to what some previous research has suggested. Rheumatoid arthritis affects an estimated 1 percent of the general population, with women three times more likely to have it. Different from age-related osteoarthritis, rheumatoid arthritis is debilitating ...

FDA Approves Actemra (tocilizumab) for the Treatment of Systemic Juvenile Idiopathic Arthritis (SJIA)

Posted 18 Apr 2011 by Drugs.com

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr 15, 2011 - Genentech, a member of the Roche Group today announced that the U.S. Food and Drug Administration (FDA) approved Actemra (tocilizumab) for the treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients two years of age and older. Actemra can be given alone or in combination with methotrexate in patients with SJIA. ...

FDA Grants Supplemental Approval for Actemra (tocilizumab)

Posted 8 Jan 2011 by Drugs.com

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jan 5, 2011 - Genentech, Inc., a member of the Roche Group, today announced that the United States (U.S.) Food and Drug Administration (FDA) has extended the Actemra (tocilizumab, RoActemra in the European Union) label to include inhibition and slowing of structural joint damage, improvement of physical function, and achievement of major clinical ...

Rheumatoid Arthritis Drug Carries Risk Of Potentially Fatal Allergic Reaction

Posted 20 Sep 2010 by Drugs.com

From Canadian Press DataFile (September 17, 2010)   TORONTO – The maker of a drug used to treat rheumatoid arthritis is updating safety information after an elderly patient taking the medication died from a severe allergic reaction. Hoffmann-La Roche Ltd., in consultation with Health Canada, said allergic reactions can occur from Actemra (tocilizumab) and patients should be closely monitored ...

Ask a Question

Further Information

Related Condition Support Groups

Giant Cell Arteritis, Rheumatoid Arthritis, Cytokine Release Syndrome, Juvenile Idiopathic Arthritis

Actemra Patient Information at Drugs.com